Plavix News and Research

RSS

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases.

24 Feb 2015

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations.

29 Aug 2014

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

18 Jun 2014

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take.

4 Jun 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Cardiologists question FDA recommendations on genetic testing before taking Plavix

Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The answer may lie in your genes, but professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration's recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate).

14 Nov 2013

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

The National Institutes of Health has renewed its prestigious Clinical and Translational Science Award (CTSA) with the Scripps Translational Science Institute (STSI) in the amount of $29 million over the next five years to support innovative research in genomics, wireless technology and bioinformatics toward individualizing medicine.

23 Oct 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients.

27 Aug 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window.

5 Jun 2013

Plavix News and Research

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Medicare to pay for hep C screenings for baby boomers

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Cardiologists question FDA recommendations on genetic testing before taking Plavix

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen receives complete response letter from FDA for XARELTO sNDA

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Study: New genetic marker predicts warfarin dose in African-Americans

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Expiring patents drive drug spending's first time fall

Study highlights cost savings of generic drugs

University of Michigan Stroke Program study examines use of tPA in stroke patients

Scientists demonstrate new approach for quickly assembling drug-like compounds

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News